April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Iris Structural Alterations in Patients Using Alpha-Adrenergic Blocking Agents
Author Affiliations & Notes
  • P.-M. Palmiero
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • T. S. Prata
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • C. V. De Moraes
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Z. Sbeity
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
    New York Medical College, Valhalla, New York
  • C. Tello
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
    New York Medical College, Valhalla, New York
  • J. M. Liebmann
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
    NYU School of Medicine, New York, New York
  • R. Ritch
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
    New York Medical College, Valhalla, New York
  • Footnotes
    Commercial Relationships  P.-M. Palmiero, None; T.S. Prata, None; C.V. De Moraes, None; Z. Sbeity, None; C. Tello, None; J.M. Liebmann, None; R. Ritch, None.
  • Footnotes
    Support  Supported by the Educational Foundation of America, Westport, CT
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6206. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.-M. Palmiero, T. S. Prata, C. V. De Moraes, Z. Sbeity, C. Tello, J. M. Liebmann, R. Ritch; Iris Structural Alterations in Patients Using Alpha-Adrenergic Blocking Agents. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6206.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess iris structural alterations associated with intraoperative floppy iris syndrome (IFIS) in patients using systemic -1-adrenergic receptor antagonists (-1ARA).

Methods: : We prospectively imaged 51 men currently or previously treated with systemic -1ARA (29 treated and 22 untreated subjects) using slit-lamp-adapted optical coherence tomography (SL-OCT) under standardized lighting conditions. Eyes with any ocular condition or use of medication that could alter iris morphology were excluded. Iris thickness was analyzed in a masked fashion at the dilator muscle region (DMR, measured at half the distance between the scleral spur and pupillary margin) and at the sphincter muscle region (SMR, 0.75 mm from the pupillary margin). The ratio between the DMR/SMR was calculated to compensate for possible intersubject variability. Photopic pupillary diameter was calculated and compared in both groups.

Results: : Most treated patients were on tamsulosin (27/29). Mean age was similar in study and control groups (70.6±7.6 vs 67.1±9.1 yr, p=0.061). Photopic pupil diameter was reduced in the study group (mean: 2.06 ± 0.5 vs 2.5 ± 0.6 mm, p=0.001). SMR was similar between groups (p=0.53). Significantly lower values were found in treated subjects for the DMR and the DMR/SMR ratio (p<0.001), which also remained significant after adjusting for pupil diameter (p<0.001). Multiple regression analysis showed that a longer duration of -1ARA treatment correlated to a reduced DMR/SMR ratio (p=0.001, r=0.47).These differences appear to be related to the duration of drug exposure and provide evidence of structural alterations to the iris dilator muscle from this class of agents.

Conclusions: : Patients using systemic -1ARA have significantly lower values of DMR thickness, DMR/SMR ratio, and smaller pupil diameter when compared to age-matched controls.

Keywords: iris • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×